GENinCode 'very busy' since IPO with US regulatory approval, driven by FDA submission

GENinCode (LON:GENI) Matthew Walls talks to Proactive London’s Katie Pilbeam about how their business is shaping up since their listing on the Alternative Investment Market (AIM).

The firm has developed a quick and easy genetic test for cardiovascular disease (CVD). Through a simple blood or saliva sample, it can analyse a patient’s medical information and genetic variants of the disease to determine a genetic score that is then used for the assessment of a patient’s cardiovascular risk.

Its SITAB system, software, bioinformatics and algorithmic platform and online cloud-based reporting, is used to process and record test results and genetic information, using algorithms and artificial intelligence, assess a patient’s risk of CVD.